News | November 25, 2023
DxVx plans to make a license-in agreement of OVM-200
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
